RecruitingNCT06209853
Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient
Correlation Between Prostate-Specific Antigen (PSA) Levels and Fluorine-18 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography (F-18 PSMA PET/CT) Scan Findings in Patients With Prostate Cancer
Sponsor
Assiut University
Enrollment
59 participants
Start Date
Jan 20, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
It is a cross sectional study aimed to correlate between PSA Levels and F-18 PSMA PET/CT Scan findings and to evaluate the impact of PET/CT findings on the patient management
Eligibility
Sex: MALE
Inclusion Criteria1
- Male Patients with pathologically proven prostate cancer who will be referred to nuclear medicine unit to perform F18 PSMA for different indications
Exclusion Criteria3
- Undifferentiated prostate cancer.
- Studies with motion artifacts, or those in which patient can't stay stable or calm during acquisition.
- Severely ill patients that hinder imaging.
Interventions
DEVICEPSMA PET/CT
Patients need no specific preparation. F-18 PSMA dose will be 3-4 MBq/kg and injected via IV route scan will be performed 90-120 min after injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06209853
Related Trials
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT070829206 locations
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT056166501 location
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT073198713 locations
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT0605683027 locations
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737274 locations